Originally published online as doi:10.1189/jlb.0306154 on August 17, 2006
Published online before print August 17, 2006
(Journal of Leukocyte Biology. 2006;80:984-993.)
© 2006
by Society for Leukocyte Biology
Type I interferon production in HIV-infected patients
Anne Hosmalin*,
,
,
,1 and
Pierre Lebon
* Institut Cochin, Département d'Immunologie, Paris, F-75014, France;
INSERM U567, Paris, F-75014, France;
CNRS, UMR-S 8104, Paris, F-75014, France; and
Université Paris 5, Faculté de Médecine René Descartes, UM3, Paris, F-75014, France
1 Correspondence: Institut Cochin, Département d'Immunologie, 27, rue du Fg St. Jacques, Bat Gustave Roussy 8eme etage, Paris 75014, France. E-mail: hosmalin{at}cochin.inserm.fr
 |
ABSTRACT
|
|---|
Type I IFNs display multiple biological effects. They have a strong antiviral action, not only directly but also indirectly through activation of the immune system. They may also have actions that are deleterious for the host. The cells that produce type I IFN are mostly plasmacytoid dendritic cells (pDC), but this depends on the viral stimulus. The migration and distribution of pDC into lymphoid organs, driven by chemokine interactions with their ligands, determines interaction with different cell types. In HIV infection, IFN production in vitro is impaired during primary infection and later in association with opportunistic infections. Circulating pDC numbers are decreased in parallel. These parameters may be used to help assess the prognosis of the disease and to monitor treatment.
Key Words: plasmacytoid dendritic cells • innate immunity • adaptive immunity • immune therapy • vaccination • primary infection • virus
|
INTRODUCTION
|
|---|
IFN can protect from viral infection [1
]. Human type I IFNs comprise 13 subtypes of IFN-
, in addition to IFN-ß, -
, -
, -
, and -
. These different IFNs share the same IFN-/-ß receptor. IFN-like molecules or type III IFNs with similar properties also include limitin (mouse), IL-28A or IFN-lambda2, IL-28B or IFN-lambda3, and IL-29 or IFN-lambda1; they share a distinct class II cytokine receptor [2
3
4
5
6
].
|
ANTIVIRAL ROLE OF TYPE I IFN
|
|---|
Antiviral role of type I IFN in vivo
The antiviral role of type I IFN was shown in vivo: anti-interferon sera administration increased dramatically the susceptibility to acute challenges with lymphocytic choriomeningitis, encephalomyocarditis, herpes simplex, maloney sarcoma, vesicular stomatitis, Newcastle disease, and influenza viruses. Mice impaired for the IFN-/-ß receptor were extremely susceptible to acute challenges with vesicular stomatitis, Semliki Forest, vaccinia, or the noncytopathic lymphocytic choriomeningitis WE strain viruses [7
8
9
10
]. IFN- is currently widely used to treat viral hepatitis B and C [11
]. A transitory peak of type I IFN was found in the plasma of SIV-infected macaques around day 10 postinfection, concomitant to the peak of plasma viral load [12
]. In draining lymph nodes from rhesus macaques infected intravaginally by SIV mac-251 or -239, elevated IFN- mRNA levels susceptible to have an antiviral activity were found too late to prevent viral replication and dissemination, whereas pro-inflammatory cytokine mRNA susceptible to recruit potential targets for SIV were found earlier [13
, 14
].When patients were studied during primary HIV infection, on average 2 months postinfection, type I IFN was not detectable in the plasma, at least by conventional methods in our hands [15
].
The capacity of natural interferon producing cells (NIPC) within PBMC to produce IFN- in vitro in response to stimulation by HSV-1 or other viral stimulation is impaired during chronic HIV infection in association with occurrence of opportunistic infections and Kaposi sarcoma [16
17
18
19
20
21
22
23
]. Conversely, IFN- production is higher in asymptomatic long-term survivors than in uninfected controls [24
]. It is dramatically impaired during primary infection [15
], adding another subclinical tendency toward immune deficiency to those that are already known during this stage, like low CD4 T cell counts [25
]. This impairment was less pronounced after a follow-up of 1 year in untreated patients, but it was corrected in highly active antiretroviral therapy (HAART) treated patients [15
]. This effect of HAART needs to be assessed in a larger cohort of patients. Primary infection is the stage in which a balance is set between viral replication and immune responses, depending on viral strain characteristics and host genetic factors [26
]. The future evolution of these patients will tell whether the loss of IFN production in vitro during this stage is detrimental for the outcome of the disease. In chronically infected, progressive patients, reconstitution of IFN- production, associated with protection from recurrent or opportunistic infection, was obtained by HAART [27
]. Interestingly, this restoration occurred earlier than that of CD4 T cell counts [28
]. Overall, a correlation seems to appear between high IFN- production capacities and low HIV viral loads and high CD4 cell counts and lack of opportunistic infections [24
, 27
, 29
]. These correlations can be related to the direct antiviral role of IFN- or -ß on HIV-1 infected cells in different models using severe combined immunodeficient mice [30
31
32
33
].
Type I IFN activation and mechanisms of action
HIV-1 stimulates plasmacytoid dendritic cells (pDC) through TLR7 [34
] and apparently CD4 [35
]. Induction of type I IFN by viruses can also be mediated through binding of viral RNA or DNA to TLR3, -8, or -9. Induction of type I IFN through TLR7, -8, and -9 is mediated by the adaptor molecule myeloid differentiation primary response protein 88 (MyD88), interferon regulatory factor (IRF)-7 and finally NF-B activation. Induction of type I IFN by viruses can also be mediated through TLR-independent pathways, involving cytoplasmic sensors, like the retinoic acid-inducible gene I (RIG-I) and the melanoma differentiation-associated gene 5 (MDA5). This leads to IRF3 activation and finally NF-B activation [36
].
Type I IFNs induce or enhance the expression of many genes [37
] through a cell transmembrane receptor composed of two subunits, IFNAR1 and IFNAR2. Binding of the receptors leads to a cascade of phosphorylation of kinases, JAK1 and Tyk2, and subsequently to the tyrosine phosphorylation of signal transducers and activators of STAT1 and STAT2. These activated STAT form a complex with IRF9, ISGF3, which translocates to the nucleus and binds to DNA sequences of IFN-stimulated genes (ISG) containing IFN-stimulated response elements (ISRE). More than 100 ISG are transcribed, and their products are involved in the different properties of interferons such as antiviral, antiproliferative, apoptosis, and immunomodulatory properties. The main ISG encode for the protein kinase stimulated by ds RNA (PKR), the 2’-5'oligoadenylate synthetases (OAS), and the myxovirus resistance GTPase (MX), but also the ISG 20. PKR is a serine threonine kinase, which, in the presence of dsRNA, phosphorylates substrates, among which the subunit of the eukaryotic initiation factor 2- (eIF2) stops protein translation. OAS, in the presence of dsRNA, synthesizes 2'5' oligoadenylates, which activate endogenous cytoplasmic RNase L (RNase L) and lead to the degradation of viral and cellular mRNA. PKR and OAS are also involved in cellular apoptosis. MxA, from the dynamin family, inhibits the RNA polymerase of influenza viruses and more generally appears to detect viral infection by sensing nucleocapsid-like structures and trapping them into specific subcellular compartments to make them unavailable for the generation of new virus particles [36
, 38
].
The antiviral activity of type I IFN can also be mediated by different actors of the immune system [3
, 36
]. Indeed, type I interferons amplify their own expression through induction of IRF-7 [39
] and through accumulation of plasmacytoid dendritic cells (pDC) [40
]. They activate the lytic potential and proliferation of NK and 
T cells and NO synthesis by macrophages. They also enhance lysis of infected cells by cytotoxic T cells or T helper type 1 cells, as well as IFN- production by T lymphocytes [41
]. During LCMV infection, the activation of CD8 T cells depends on their ability to respond to type I IFN [42
43
44
45
]. Type I IFN increase class I MHC expression on all cell types, perhaps counteracting the effect of HIV Nef [46
, 47
], and thus potentially increasing recognition and lysis by specific CD8+ T lymphocytes. In addition, cross-presentation by DC is enhanced through the action of virally-induced type I IFN [48
], and this presentation pathway is probably crucial so as to enhance viral antigen presentation while avoiding autoimmune recognition [49
50
51
52
53
]. Conversely, high levels of type I IFN inhibit IL-12 expression and IL-12 activation of NK cell IFN- production [41
]. STAT1 has a critical role in many of these effects [36
].
Role of type I IFN on HIV replication in vitro
Type I IFNs inhibit the replication of HIV-1 [54
55
56
], especially when cells are pretreated by IFN before infection; this effect acts on the integration and the reverse transcriptase activity of the virus [57
, 58
]. When cells are treated by IFN after infection, the antiviral effect is less pronounced [57
, 59
]. IFN is supposed to block the association of RNAs to polyribosomes and inhibit viral particle assembly through posttranslational modification of viral proteins. A weak but continuous production of IFN-ß by the PBMC of healthy donors or of HIV+ patients, after transduction by a retroviral vector encoding for IFN-ß, protects them from HIV-1 infection; blockade of viral infection using this mechanism seems to occur at a very early stage of HIV-1 replication [60
]. HIV-1 induces directly the synthesis of the MxA gene [61
] and of the 2-5A synthetase [62
] but not of other interferon-inducible genes [61
]. The direct induction of the 2-5A synthetase makes HIV-infected cells resistant to another viral infection, particularly vesicular stomatitis virus (VSV) infection and may play a role in the control of HIV protein synthesis. Indeed in vitro, HIV-1 production is strongly inhibited by transfection of the 2-5A synthetase gene [63
]. 2’-5' Oligoadenylates and analogs can inhibit the reverse transcriptase activity of HIV-1 [62
].
Viral escape to the effects of type I IFN
Viruses have the genetic capacity to downmodulate IFN production or inhibit responses to IFN [36
, 64
]. Inhibition of IFN induction in infected cells occurs through viral proteins that block the activation of IRF-3 after interaction with ds RNA, preventing the activation through TLR3 or TLR-independent sensors such as RIG-I and MDA 5 [36
, 64
]. Some strains of RSV and measles inhibit IFN production by pDCs, although the molecular mechanisms involved are unknown [64
]. Inhibition of the response of infected cells to IFN has recently been demonstrated in the case of cytomegaloviruses and involves specific targeting and degradation of STAT-2 [64
]. No evident inhibition of IFN induction by HIV was reported. A sequence in the 5' HIV-1 long terminal repeat (LTR) contains a binding site for transcription factors of the IRF family. IRF-1 is produced early upon virus entry in CD4+ T cells and before expression of Tat. IRF-1 activates HIV-1 long terminal repeat (LTR) transcription and also cooperates with Tat in amplifying virus gene transcription and replication. IRF-1 is mostly expressed under the action of IFN- in activated T cells and not under the action of type 1 IFN [65
]. The HIV-1 transactivating response (TAR) RNA can activate the 2-5A synthetase and PKR [66
]. However, HIV induces the expression of the RNase L inhibitor, which antagonizes the binding of 2’-5'A oligoadenylates to RNase L [67
]. PKR can be activated by HIV through binding to the ds RNA region TAR of the LTR [68
]. The transactivating protein Tat and the cellular TAR RNA binding protein (TRBP) also bind to TAR and to PKR and behave as inhibitors of the autophosphorylation of PKR during viral infection, therefore inhibiting its action on the eIF2 substrate and on protein synthesis. TRBP is part of a Dicer complex and is required for RNA interference; it is perhaps diverted by HIV-1 [69
70
71
]. Moreover, PKR can phosphorylate HIV Tat and enhance its capacity to transactivate the LTR [72
]. TAR and Tat, therefore, participate actively in viral escape to the effects of type I IFN.
|
ADVERSE ROLES OF TYPE I IFN IN VIRAL INFECTION
|
|---|
All the effector mechanisms of the immune system that reduce viral replication have mirroring adverse effects on the host. Type I and type II IFNs induce a cytotoxic activity in antigen presenting cells. HIV itself, like other viruses, induces a cytotoxic activity in monocytes [73
], DC [74
], and CD4 T cells themselves [35
] against infected CD4 T lymphocytes but also against uninfected cells. TRAIL mediates at least in part the cytotoxicity of monocytes, in a type I IFN-dependent way [75
]. In vitro, HIV-1 gp120 induces in CD4 T lymphocytes both sensitivity to TRAIL directly and TRAIL expression indirectly, through the stimulation of CD4, which induces type I IFN secretion by pDC [35
]. These cytotoxic mechanisms, as well as those stimulated in NK cells [76
] or bystander T cells, can be responsible for the high susceptibility to apoptosis of uninfected CD4 T cells that are found in HIV-infected patients [77
]. Indeed, TRAIL neutralization in HIV-1 infected Hu-PBL-NOD-SCID mice inhibits human CD4 T cell apoptosis induced by HIV-1 infection [78
]. Moreover, soluble TRAIL is found in the plasma of HIV-1 infected patients and is decreased by HAART in correlation with viral load [75
]. In addition, in the SCID-hu Thy/liv mouse model and in thymus organ cultures, HIV-1 induces pDC to secrete type I IFN, which in turn up-regulates MHC class I molecule expression on most thymocytes [79
]. This may lead to thymic selection of dysfunctional CD8+ T lymphocytes [80
].
Early work has suggested a deleterious effect of high concentrations of IFN- (i.e., inhibition of T cell proliferation, inhibition of chemokine production) and even proposed immunization against this cytokine as a therapeutic approach against AIDS [81
, 82
]. A dichotomy may exist between positive and negative effects of IFN- in the early vs. late stages of the disease. IFN- has been shown to be potentially beneficial on HIV viral loads during early stages of infection, but not later [83
]. In chronic lymphocytic choriomeningitis virus (LCMV) infection, administration of anti-IFN serum inhibits pathogenesis [84
]. During acute LCMV infection in mice, while type I IFN activate effector CD8 T cell responses, they also prevent renewal of the DCs [85
] and drive the early attrition of CD8 T cells [86
, 87
]. Besides their effects in viral infections, type I IFN can enhance autoimmunity; particularly, the high levels of type I IFN found in the sera of systemic lupus erythematosus induce differentiation of monocytes into DC and probably exacerbate the pathogenesis of the disease [88
, 89
]. How the outcome of the balance between negative and positive effects of IFN on antiviral immune responses is regulated needs further investigation but it may depend on the kinetics, levels and anatomical location of IFN release.
|
PLASMACYTOID DENDRITIC CELLS AND OTHER CELL TYPES RESPONSIBLE FOR TYPE I IFN PRODUCTION
|
|---|
The major human peripheral blood mononuclear cell subset that was responsible for the production in vitro of IFN- in response to influenza, Sendai, and Newcastle disease viruses was first identified as an HLA-DR+, DC-related population lacking the markers for other cell lineages [90
, 91
]. This population was nonadherent and stimulated allogeneic T cell proliferation poorly [92
]. NIPC or IPC were eventually identified as plasmacytoid dendritic cells (pDC) [93
94
95
96
97
98
99
100
101
102
103
]. They are present in lymph nodes, tonsils, and blood with a very low frequency and they produce 100 times more type I IFN per cell than monocytes.When they are depleted in vivo, the response to mCMV infection or to CpG or oligoribonucleotide injection is abolished [103
104
105
106
]. In some infections, like LCMV infection, pDC are not the major population responsible for the early IFN- response [104
]. In humans, pDC produce IFN- [107
] after stimulation by live or inactivated HIV [108
, 109
]. IFN- in turn sustains pDC survival [110
, 111
].
pDC counts are reduced during chronic as well as primary HIV-1 infection [22
23
24
, 27
, 112
113
114
115
116
]. A correlation with plasma viral load [24
, 27
, 112
] and/or with peripheral CD4 T cell counts [112
, 114
, 115
, 117
] was found in most, but not all, studies [22
, 114
]. A correlation with lymphoproliferative responses against HIV-1 p24 was found in one study [114
]. In a pediatric study, pDC counts were found to be lower in viremic children with a history of decreasing CD4 T cell percentages compared with children with stable CD4 T cell counts [115
]. The pDC count defect is already found at the onset of primary infection. Strikingly, at the onset of primary HIV infection and not at later time points in HIV or HCV [118
] infection, the correlation between pDC counts and type I IFN production is lost [15
], indicating loss of function in some pDC.
Why are circulating pDC numbers reduced in HIV patients? A central bone marrow precursor defect may be involved, as for T lymphocyte precursors in macaques [119
, 120
]. pDC may also be destroyed in the periphery by the virus itself. Indeed, HIV infects pDC in vitro with cytopathogenicity [108
, 121
, 122
], and infected pDC are found in the tonsils, thymus, and blood from HIV-infected patients [123
, 124
]. pDC may also strive less because of lower IFN production [29
] or defective interaction with CD4 T lymphocytes [124
]. In any case, pDC probably home to lymph nodes during HIV infection [125
126
127
]. In the SIV infection model, many activated DC were found in lymphoid tissues in primary or asymptomatic infection, but at the stage of AIDS only few activated CD83+ DC were found in the lymph nodes [127
]. This finding was consistent with the lower capacity to up-regulate CD83, a terminal differentiation molecule, on spleen DC from late-stage HIV-infected patients [128
].
Thus, the mechanisms responsible for the loss of circulating DC are not identified but may reflect different mechanisms, including homing to the lymphoid organs. This homing may help induce antiviral responses on one hand and hyperactivation of the immune system on the other; whereas a lack of DC activation in the lymphoid organs may reflect the failure of the immune system in AIDS.
|
HOMING AND CELL INTERACTION
|
|---|
Compartmentalization is a key to understanding all biological responses, including immune responses. Type I IFN production will occur where the pDC are driven by viral stimulation, and relevant data must be sought not only in blood but also in lymphoid organs [129
130
131
]. Migration of DC upon stimulation is selectively driven by the successive expression of different chemokine receptors and integrins [132
]. Human pDC express L-selectin (CD62L), which probably drives their entry into the lymph nodes through high endothelial venules in the steady state, likewise to what has been demonstrated in mice [94
, 100
, 133
, 134
]. During bacterial- or viral-driven inflammation, the expression of CXCR3 is required for pDC migration into the lymph nodes in a CXCL9- and E-selectin-dependent manner [135
]. Plasmacytoid DC migration into inflamed tissues or tumors can also be mediated by CXCR4 and driven by SDF-1/CXCL12 [136
]; by ChemR23, driven by chemerin [137
]; and by CCR1, CCR2, and CCR5, receptors for inflammatory cytokines [102
]. Once activated, pDC express CCR7, the receptor for the chemokines MIP3ß/CCL19 and SLC or 6Ckine/CCL212, which attract them into the T cell areas of secondary lymphoid organs [138
]. In HIV infection, homing of pDC to the lymph nodes [125
] would be consistent with the in vitro induction by HIV-1 of CCR7 expression and of migration toward CCL19 [139
]. In mice, pDC differ from mDC in the in vivo response to TLR ligands, in terms of pattern and type I IFN requirement for activation and migration [140
].
Human pDC have a successive chemokine expression pattern susceptible to attract other cell populations—first effector cells (cytotoxic T and NK cells and neutrophils), then effector memory T cells, then naive T and B lymphocytes—while they mature and putatively progress toward the T cell zones of the secondary lymphoid organs [141
142
143
144
]. In addition, the cross-talk between mDC, pDC, monocytes, T and B lymphocytes, neutrophils, and NK cells in HIV infection needs to be explored [115
, 116
, 145
146
147
]. The relations between pDC and the regulatory T cells that hinder antiviral effector responses as well as pathogenic hyperactivation of the immune system in HIV and SIV infections [148
149
150
151
152
153
154
] will be interesting to study, because pDC can induce regulatory T cells [155
156
157
]. Indeed, semi-mature pDC and mDC and FoxP3+CD4+ T cells were found in the lymph nodes from untreated HIV+ patients in higher proportions than in lymph nodes from treated HIV+ patients or from HIV– patients [158
].
CCR5- and CXCR4-using HIV-1 isolates stimulate pDC maturation (up-regulation of CD83, CCR7, costimulation molecules, migration toward CCL19) and secretion of TNF- and IFN- [108
, 139
, 159
]. In contrast, in response mostly to CCR5-using HIV-1 isolates, depending on the laboratories and probably on the concentration used, mDC undergo at least partial maturation but do not secrete either type I IFN nor bioactive IL-12 p70 [159
, 160
]. However, when pDC and mDC are co-cultured with HIV, IFN and TNF- secretion by pDC induces mDC maturation [139
]. Virus replication is enhanced after pDC treatment with CD40L and antibodies against IFN-, probably because of the reduction in IFN- production [122
, 123
]. HIV-1 infection is transferred from pDC as well as from mDC, most efficiently toward antigen-specific CD4+ T cells [161
].
|
PREDICTIVE FACTORS DURING HIV INFECTION
|
|---|
The results described above hint that pDC counts (when they will be standardized [15
]) and/or in vitro type I IFN production might be used as predictive factors during HIV infection, as well as in other infections. Indeed, in dengue virus infection, children who developed hemorrhagic dengue fever had an early decrease in circulating pDC levels, which was not found in those who had more benign forms of the disease [162
]. In tuberculosis, pDC count recovery correlates with successful antibiotic treatment [163
]. Other predictive factors in HIV infection include: baseline levels of CD4 T cell counts and plasma HIV RNA; the nadir CD4 T cell count, as well as parameters such as CD4 T cell counts; proviral DNA load in peripheral blood mononuclear cells; anti-p24 lymphoproliferative response at the time of treatment interruption; and immunologic setpoint activation, as measured by median density of CD38 molecules on CD4 and CD8 T cells [164
165
166
167
168
169
]. However, these factors are not completely predictive of disease progression in at least three circumstances.
The first circumstance is the decision to treat by HAART early during acute or primary infection. Here, the putative restoration of type I IFN production under HAART [15
] adds an additional argument, together with the reduction of CD8 T cell oligoclonality [170
] and the increase in specific CD4 responses [171
, 172
], for the use of HAART to preserve the immune system while viral populations are homogeneous, thus preventing virus spreading. However, there is limited durability [173
], early resistance induction [169
, 174
], long-term drug-associated toxicity, and lack of adherence [26
].
The second circumstance is to evaluate HAART success: a recovery in pDC counts, at least partial, or in type I IFN production, was obtained in several studies but not all [22
], through HAART during chronic infection [27
, 117
] and probably during primary infection [15
, 175
]. This recovery sometimes correlated with a recovery in CD4 T cell counts and/or a decrease in viral load [27
, 113
, 117
]. pDC count recovery was earlier and more pronounced than CD4 count recovery [28
, 117
].
The third circumstance is the counseling of patients who request HAART interruption because of side effects. One study on patients with primary HIV-1 infection with undetectable viral loads under HAART showed that pDC count recovery during HAART correlated with the ability to control spontaneously replication after treatment interruption [175
]. This pilot study needs further confirmation in large cohorts of chronically infected patients [167
]. pDC counts, in addition to baseline viral load and other predictive factors, might help in counseling the patients on their risk of viral replication rebound.
|
Type I IFN administration or stimulation as therapy against HIV infection
|
|---|
IFN- is currently being tested in clinical trials, particularly during primary HIV infection, where it might supplement defective production [15
] and where promising results were obtained [176
], as formerly in asymptomatic chronic infection [83
]. Type I IFN production might also be stimulated by TLR ligands, if pDC can still respond. More interestingly, it might be stimulated by CpG or imiquimod analogs for antiviral protection at the mucosal level [177
178
179
180
]. However, caution must be exercised to avoid hyperactivation of the mucosal immune system that would increase viral replication [181
]. Finally, IFN- is a strong adjuvant in vaccination [182
]. It induces the differentiation of monocyte-derived DC for cell therapy [183
, 184
]. CpG oligonucleotides can stimulate not only pDC, but also B cells [185
], for systemic and mucosal vaccination; indeed they induce strong local T cell immune responses in the genital tract and cross-clade protection [186
, 187
]. Therefore, type I IFN administration or stimulation may have strong potential in future immune therapies against HIV.
|
CONCLUSION
|
|---|
Correlative data indicate that type I IFN produced by pDC have a role in the control of HIV infection, although pathogenicity may also be induced [188
189
190
191
192
193
194
195
196
]. The role of homing into lymphoid organs and of interactions with other cell types still needs intensive studying during this infection. Plasmacytoid DC counts and/or of type I IFN production tests in vitro might be used as predictive factors during HIV infection, to evaluate HAART success or to counsel patients who want to interrupt HAART about their risk of viral rebound. Immune therapy and vaccination can use either IFN- itself or its induction by TLR ligands to obtain better viral replication control and stimulation of antigen-specific immune responses. The mechanisms of viral escape to the effects of type I IFN need to be understood further to lead to better targeted therapies.
|
ACKNOWLEDGEMENTS
|
|---|
The authors thank Michaela Müller-Trutwin (Pasteur Institute, Paris), Stéphanie Louis, Michelina Nascimbeni, Concepción Marañón, Miriam Lichtner, Sandrine Kahi, Leyla Develioglu, Isabelle Kamga, Aurélie Teissonnière, Ludovic Fery, Laurent Chorro, Seckou Diocou, Guillaume Hoeffel, and Jérôme Pacanowski (all from the Antigen Presentation by Dendritic Cell Team, Cochin Institute, Paris) and Martine Sinet (INSERM E0109, Le Kremlin-Bicêtre, France), as well as all members of the Dendritic Cells Workgroup from the Agence Nationale de la Recherche contre le SIDA et les hépatites virales (ANRS, Actions coordonnées 19 and 31), for stimulating discussions; and Marc Dalod (Centre d’Immunologie de Marseille, Luminy, Marseille, France), Rémi Cheynier and Stéphanie Beq (both from the Pasteur Institute, Paris) for greatly improving the manuscript. Work sponsored by the ANRS and Sidaction.
Received March 4, 2006;
revised May 3, 2006;
accepted July 5, 2006.
|
REFERENCES
|
|---|
- Isaacs, A., Lindenmann, J. (1957) Virus interference. I. The interferon Proc. R. Soc. Lond. B. Biol. Sci. 147,258-267[Medline]
- Pestka, S., Krause, C. D., Sarkar, D., Walter, M. R., Shi, Y., Fisher, P. B. (2004) Interleukin-10 and related cytokines and receptors Annu. Rev. Immunol. 22,929-979[CrossRef][Medline]
- Tough, D. F. (2004) Type I interferon as a link between innate and adaptive immunity through dendritic cell stimulation Leuk. Lymphoma 45,257-264[CrossRef][Medline]
- Lebon, P. (1997) Interférons et maladies infectieuses Encyclopedie Medico-Chirurgicale Vol. 8-006-10,1-8 Elsevier Paris.
- Sheppard, P., Kindsvogel, W., Xu, W., Henderson, K., Schlutsmeyer, S., Whitmore, T. E., Kuestner, R., Garrigues, U., Birks, C., Roraback, J., et al (2003) IL-28, IL-29 and their class II cytokine receptor IL-28R Nat. Immunol. 4,63-68[CrossRef][Medline]
- Kotenko, S. V., Gallagher, G., Baurin, V. V., Lewis-Antes, A., Shen, M., Shah, N. K., Langer, J. A., Sheikh, F., Dickensheets, H., Donnelly, R. P. (2003) IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex Nat. Immunol. 4,69-77[CrossRef][Medline]
- Fauconnier, B. (1971) Effect of an anti-interferon serum on experimental viral pathogenicity in vivo Pathol. Biol. (Paris) 19,575-578[Medline]
- Gresser, I., Tovey, M. G., Bandu, M. E., Maury, C., Brouty-Boye, D. (1976) Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum. I. Rapid evolution of encephalomyocarditis virus infection J. Exp. Med. 144,1305-1315[Abstract/Free Full Text]
- Gresser, I., Tovey, M. G., Maury, C., Bandu, M. T. (1976) Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum. II. Studies with herpes simplex, Moloney sarcoma, vesicular stomatitis, Newcastle disease, and influenza viruses J. Exp. Med. 144,1316-1323[Abstract/Free Full Text]
- Muller, U., Steinhoff, U., Reis, L. F., Hemmi, S., Pavlovic, J., Zinkernagel, R. M., Aguet, M. (1994) Functional role of type I and type II interferons in antiviral defense Science 264,1918-1921[Abstract/Free Full Text]
- Pol, S., Vallet-Pichard, A., Fontaine, H. (2002) Hepatitis C and human immune deficiency coinfection at the era of highly active antiretroviral therapy J. Viral Hepat. 9,1-8[CrossRef][Medline]
- Khatissian, E., Tovey, M. C., Cumont, M. C., Manceaux, V., Lebon, P., Montagnier, L., Hurtrel, B., Chakrabarti, L. (1996) The relationship between the interferon alpha response and viral burden in primary SIV infection AIDS Res. Hum. Retroviruses 12,1273-1278[Medline]
- Abel, K., Compton, L., Rourke, T., Montefiori, D., Lu, D., Rothaeusler, K., Fritts, L., Bost, K., Miller, C. J. (2003) Simian-human immunodeficiency virus SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239 is independent of the route of immunization and is associated with a combination of cytotoxic T-lymphocyte and alpha interferon responses J. Virol. 77,3099-3118[Abstract/Free Full Text]
- Abel, K., Rocke, D. M., Chohan, B., Fritts, L., Miller, C. J. (2005) Temporal and anatomic relationship between virus replication and cytokine gene expression after vaginal simian immunodeficiency virus infection J. Virol. 79,12164-12172[Abstract/Free Full Text]
- Kamga, I., Develioglu, L., Lichtner, M., Kahi, S., Marañón, C., Deveau, C., Meyer, L., Goujard, C., Sinet, M., Lebon, P., et al (2005) Type I interferon production is profoundly impaired in primary HIV-1 infection J. Infect. Dis. 192,303-310[CrossRef][Medline]
- Lopez, C., Fitzgerald, P. A., Siegal, F. P. (1983) Severe acquired immune deficiency syndrome in male homosexuals: diminished capacity to make interferon-alpha in vitro associated with severe opportunistic infections J. Infect. Dis. 148,962-966[Medline]
- Siegal, F. P., Lopez, C., Fitzgerald, P. A., Shah, K., Baron, P., Leiderman, I. Z., Imperato, D., Landesman, S. (1986) Opportunistic infections in acquired immune deficiency syndrome result from synergistic defects of both the natural and adaptive components of cellular immunity J. Clin. Invest. 78,115-123[Medline]
- Howell, D. M., Feldman, S. B., Kloser, P., Fitzgerald-Bocarsly, P. (1994) Decreased frequency of functional natural interferon-producing cells in peripheral blood of patients with the acquired immune deficiency syndrome Clin. Immunol. Immunopathol. 71,223-230[CrossRef][Medline]
- Ferbas, J. J., Toso, J. F., Logar, A. J., Navratil, J. S., Rinaldo, C. R. (1994) CD4+ blood dendritic cells are potent producers of IFN- in response to in vitro HIV infection J. Immunol. 152,4649-4662[Abstract]
- Ferbas, J., Navratil, J., Logar, A., Rinaldo, C. (1995) Selective decrease in human immunodeficiency virus type 1 (HIV-1)-induced alpha interferon production by peripheral blood mononuclear cells during HIV-1 infection Clin. Diagn. Lab. Immunol. 2,138-142[Medline]
- Feldman, S. B., Milone, M. C., Kloser, P., Fitzgerald-Bocarsly, P. (1995) Functional deficiencies in two distinct interferon alpha-producing cell populations in peripheral blood mononuclear cells from human immunodeficiency virus seropositive patients J. Leukoc. Biol. 57,214-220[Abstract]
- Chehimi, J., Campbell, D. E., Azzoni, L., Bacheller, D., Papasavvas, E., Jerandi, G., Mounzer, K., Kostman, J., Trinchieri, G., Montaner, L. J. (2002) Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals J. Immunol. 168,4796-4801[Abstract/Free Full Text]
- Anthony, D. D., Yonkers, N. L., Post, A. B., Asaad, R., Heinzel, F. P., Lederman, M. M., Lehmann, P. V., Valdez, H. (2004) Selective impairments in dendritic cell-associated function distinguish hepatitis C virus and HIV infection J. Immunol. 172,4907-4916[Abstract/Free Full Text]
- Soumelis, V., Scott, I., Gheyas, F., Bouhour, D., Cozon, G., Cotte, L., Huang, L., Levy, J. A., Liu, Y. J. (2001) Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients Blood 98,906-912[Abstract/Free Full Text]
- Vanhems, P., Voirin, N., Hirschel, B., Cooper, D. A., Vizzard, J., Carr, A., Perrin, L. (2003) Brief report: incubation and duration of specific symptoms at acute retroviral syndrome as independent predictors of progression to AIDS J. Acquir. Immune Defic. Syndr. 32,542-544[Medline]
- Perrin, L. (1999) Primary HIV infection Antivir. Ther. 4(Suppl 3),13-18[Medline]
- Finke, J. S., Shodell, M., Shah, K., Siegal, F. P., Steinman, R. M. (2004) Dendritic cell numbers in the blood of HIV-1 infected patients before and after changes in antiretroviral therapy J. Clin. Immunol. 24,647-652[CrossRef][Medline]
- Siegal, F. P., Fitzgerald-Bocarsly, P., Holland, B. K., Shodell, M. (2001) Interferon-alpha generation and immune reconstitution during antiretroviral therapy for human immunodeficiency virus infection AIDS 15,1603-1612[CrossRef][Medline]
- Feldman, S., Stein, D., Amrute, S., Denny, T., Garcia, Z., Kloser, P., Sun, Y., Megjugorac, N., Fitzgerald-Bocarsly, P. (2001) Decreased interferon-alpha production in HIV-infected patients correlates with numerical and functional deficiencies in circulating type 2 dendritic cell precursors Clin. Immunol. 101,201-210[CrossRef][Medline]
- Sanhadji, K., Leissner, P., Firouzi, R., Pelloquin, F., Kehrli, L., Marigliano, M., Calenda, V., Ottmann, M., Tardy, J. C., Mehtali, M., et al (1997) Experimental gene therapy: the transfer of Tat-inducible interferon genes protects human cells against HIV-1 challenge in vitro and in vivo in severe combined immunodeficient mice AIDS 11,977-986[CrossRef][Medline]
- Lapenta, C., Santini, S. M., Proietti, E., Rizza, P., Logozzi, M., Spada, M., Parlato, S., Fais, S., Pitha, P. M., Belardelli, F. (1999) Type I interferon is a powerful inhibitor of in vivo HIV-1 infection and preserves human CD4(+) T cells from virus-induced depletion in SCID mice transplanted with human cells Virology 263,78-88[CrossRef][Medline]
- Vieillard, V., Jouveshomme, S., Leflour, N., Jean-Pierre, E., Debre, P., De Maeyer, E., Autran, B. (1999) Transfer of human CD4(+) T lymphocytes producing beta interferon in Hu-PBL-SCID mice controls human immunodeficiency virus infection J. Virol. 73,10281-10288[Abstract/Free Full Text]
- Gurney, K. B., Colantonio, A. D., Blom, B., Spits, H., Uittenbogaart, C. H. (2004) Endogenous IFN-alpha production by plasmacytoid dendritic cells exerts an antiviral effect on thymic HIV-1 infection J. Immunol. 173,7269-7276[Abstract/Free Full Text]
- Beignon, A.S., McKenna, K., Skoberne, M., Manches, O., Dasilva, I., Kavanagh, D.G., Larsson, M., Gorelick, R.J., Lifson, J.D., Bhardwaj, N. (2005) Endocytosis of HIV-1 activates plasmacytoid dendritic cells via toll-like receptor-viral RNA interactions J. Clin. Invest. 115,3265-3275[CrossRef][Medline]
- Herbeuval, J. P., Hardy, A. W., Boasso, A., Anderson, S. A., Dolan, M. J., Dy, M., Shearer, G. M. (2005) Regulation of TNF-related apoptosis-inducing ligand on primary CD4+ T cells by HIV-1: role of type I IFN-producing plasmacytoid dendritic cells Proc. Natl. Acad. Sci. USA 102,13974-13979[Abstract/Free Full Text]
- Garcia-Sastre, A., Biron, C. A. (2006) Type 1 interferons and the virus-host relationship: a lesson in detente Science 312,879-882[Abstract/Free Full Text]
- Der, S. D., Zhou, A., Williams, B. R., Silverman, R. H. (1998) Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays Proc. Natl. Acad. Sci. USA 95,15623-15628[Abstract/Free Full Text]
- Haller, O., Kochs, G. (2002) Interferon-induced mx proteins: dynamin-like GTPases with antiviral activity Traffic 3,710-717[CrossRef][Medline]
- Marie, I., Durbin, J. E., Levy, D. E. (1998) Differential viral induction of distinct interferon-alpha genes by positive feedback through interferon regulatory factor-7 EMBO J. 17,6660-6669[CrossRef][Medline]
- Dalod, M., Hamilton, T., Salomon, R., Salazar-Mather, T. P., Henry, S. C., Hamilton, J. D., Biron, C. A. (2003) Dendritic cell responses to early murine cytomegalovirus infection: subset functional specialization and differential regulation by interferon alpha/beta J. Exp. Med. 197,885-898[Abstract/Free Full Text]
- Biron, C. A. (2001) Interferons alpha and beta as immune regulators–a new look Immunity 14,661-664[CrossRef][Medline]
- Le Bon, A., Durand, V., Kamphuis, E., Thompson, C., Bulfone-Paus, S., Rossmann, C., Kalinke, U., Tough, D. F. (2006) Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming J. Immunol. 176,4682-4689[Abstract/Free Full Text]
- Aichele, P., Unsoeld, H., Koschella, M., Schweier, O., Kalinke, U., Vucikuja, S. (2006) CD8 T cells specific for lymphocytic choriomeningitis virus require type I IFN receptor for clonal expansion J. Immunol. 176,4525-4529[Abstract/Free Full Text]
- Thompson, L. J., Kolumam, G. A., Thomas, S., Murali-Krishna, K. (2006) Innate inflammatory signals induced by various pathogens differentially dictate the IFN-I dependence of CD8 T cells for clonal expansion and memory formation J. Immunol. 177,1746-1754[Abstract/Free Full Text]
- Marrack, P., Kappler, J., Mitchell, T. (1999) Type I interferons keep activated T cells alive J. Exp. Med. 189,521-530[Abstract/Free Full Text]
- Schwartz, O., Marechal, V., Le Gall, S., Lemonnier, F., Heard, J. M. (1996) Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein Nat. Med. 2,338-342[CrossRef][Medline]
- Andrieu, M., Chassin, D., Desoutter, J. F., Bouchaert, I., Hanau, D., Guillet, J. G., Hosmalin, A. (2001) HIV-1 Nef protein induces a down-regulation of the dendritic cell surface expression of MHC class I and impairs antigen presentation to CTL AIDS Res. Hum. Retroviruses 17,1365-1370[CrossRef][Medline]
- Le Bon, A., Etchart, N., Rossmann, C., Ashton, M., Hou, S., Gewert, D., Borrow, P., Tough, D. F. (2003) Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon Nat. Immunol. 4,1009-1015[CrossRef][Medline]
- Rock, K. L., Shen, L. (2005) Cross-presentation: underlying mechanisms and role in immune surveillance Immunol. Rev. 207,166-183[CrossRef][Medline]
- Chen, W., Masterman, K. A., Basta, S., Mansour Haeryfar, S. M., Dimopoulos, N., Knowles, B., Bennink, J. R., Yewdell, J. W. (2004) Cross-priming of CD8+ T cells by viral and tumor antigens is a robust phenomenon Eur. J. Immunol. 34,194-199[CrossRef][Medline]
- Ackerman, A. L., Cresswell, P. (2004) Cellular mechanisms governing cross-presentation of exogenous antigens Nat. Immunol. 5,678-684[CrossRef][Medline]
- Lizee, G., Basha, G., Tiong, J., Julien, J. P., Tian, M., Biron, K. E., Jefferies, W. A. (2003) Control of dendritic cell cross-presentation by the major histocompatibility complex class I cytoplasmic domain Nat. Immunol. 4,1065-1073[CrossRef][Medline]
- Marañón, C., Desoutter, J. F., Hoeffel, G., Cohen, W., Hanau, D., Hosmalin, A. (2004) Dendritic cells cross-present HIV antigens from live as well as apoptotic infected CD4+ T lymphocytes Proc. Natl. Acad. Sci. USA 101,6092-6097[Abstract/Free Full Text]
- Poli, G., Orenstein, J. M., Kinter, A., Folks, T. M., Fauci, A. S. (1989) Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines Science 244,575-577[Abstract/Free Full Text]
- Bednarik, D. P., Mosca, J. D., Raj, N. B., Pitha, P. M. (1989) Inhibition of human immunodeficiency virus (HIV) replication by HIV-trans-activated alpha 2-interferon Proc. Natl. Acad. Sci. USA 86,4958-4962[Abstract/Free Full Text]
- Gendelman, H. E., Baca, L. M., Turpin, J., Kalter, D. C., Hansen, B., Orenstein, J. M., Dieffenbach, C. W., Friedman, R. M., Meltzer, M. S. (1990) Regulation of HIV replication in infected monocytes by IFN-alpha. Mechanisms for viral restriction J. Immunol. 145,2669-2676[Abstract]
- Meylan, P. R., Guatelli, J. C., Munis, J. R., Richman, D. D., Kornbluth, R. S. (1993) Mechanisms for the inhibition of HIV replication by interferons-alpha, -beta, and -gamma in primary human macrophages Virology 193,138-148[CrossRef][Medline]
- Shirazi, Y., Pitha, P. M. (1993) Interferon alpha-mediated inhibition of human immunodeficiency virus type 1 provirus synthesis in T-cells Virology 193,303-312[CrossRef][Medline]
- Agy, M. B., Acker, R. L., Sherbert, C. H., Katze, M. G. (1995) Interferon treatment inhibits virus replication in HIV-1- and SIV-infected CD4+ T-cell lines by distinct mechanisms: evidence for decreased stability and aberrant processing of HIV-1 proteins Virology 214,379-386[CrossRef][Medline]
- Vieillard, V., Lauret, E., Maguer, V., Jacomet, C., Rozenbaum, W., Gazzolo, L., De Maeyer, E. (1995) Autocrine interferon-beta synthesis for gene therapy of HIV infection: increased resistance to HIV-1 in lymphocytes from healthy and HIV-infected individuals AIDS 9,1221-1228[Medline]
- Baca, L. M., Genis, P., Kalvakolanu, D., Sen, G., Meltzer, M. S., Zhou, A., Silverman, R., Gendelman, H. E. (1994) Regulation of interferon-alpha-inducible cellular genes in human immunodeficiency virus-infected monocytes J. Leukoc. Biol. 55,299-309[Abstract]
- Schroder, H. C., Kelve, M., Muller, W. E. (1994) The 2-5A system and HIV infection Prog. Mol. Subcell. Biol. 14,176-197[Medline]
- Schroder, H. C., Suhadolnik, R. J., Pfleiderer, W., Charubala, R., Muller, W. E. (1992) (2'-5') Oligoadenylate and intracellular immunity against retrovirus infection Int. J. Biochem. 24,55-63[CrossRef][Medline]
- Hengel, H., Koszinowski, U.H., Conzelmann, K.K. (2005) Viruses know it all: new insights into IFN networks Trends Immunol. 26,396-401[CrossRef][Medline]
- Sgarbanti, M., Borsetti, A., Moscufo, N., Bellocchi, M. C., Ridolfi, B., Nappi, F., Marsili, G., Marziali, G., Coccia, E. M., Ensoli, B., et al (2002) Modulation of human immunodeficiency virus 1 replication by interferon regulatory factors J. Exp. Med. 195,1359-1370[Abstract/Free Full Text]
- Maitra, R. K., McMillan, N. A., Desai, S., McSwiggen, J., Hovanessian, A. G., Sen, G., Williams, B. R., Silverman, R. H. (1994) HIV-1 TAR RNA has an intrinsic ability to activate interferon-inducible enzymes Virology 204,823-827[CrossRef][Medline]
- Martinand, C., Montavon, C., Salehzada, T., Silhol, M., Lebleu, B., Bisbal, C. (1999) RNase L inhibitor is induced during human immunodeficiency virus type 1 infection and down regulates the 2-5A/RNase L pathway in human T cells J. Virol. 73,290-296[Abstract/Free Full Text]
- McMillan, N. A., Chun, R. F., Siderovski, D. P., Galabru, J., Toone, W. M., Samuel, C. E., Mak, T. W., Hovanessian, A. G., Jeang, K. T., Williams, B. R. (1995) HIV-1 Tat directly interacts with the interferon-induced, double-stranded RNA-dependent kinase, PKR Virology 213,413-424[CrossRef][Medline]
- Chendrimada, T. P., Gregory, R. I., Kumaraswamy, E., Norman, J., Cooch, N., Nishikura, K., Shiekhattar, R. (2005) TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing Nature 436,740-744[CrossRef][Medline]
- Haase, A. D., Jaskiewicz, L., Zhang, H., Laine, S., Sack, R., Gatignol, A., Filipowicz, W. (2005) TRBP, a regulator of cellular PKR and HIV-1 virus expression, interacts with Dicer and functions in RNA silencing EMBO Rep. 6,961-967[Medline]
- Gatignol, A., Laine, S., Clerzius, G. (2005) Dual role of TRBP in HIV replication and RNA interference: viral diversion of a cellular pathway or evasion from antiviral immunity? Retrovirology 2,65[CrossRef][Medline]
- Endo-Munoz, L., Warby, T., Harrich, D., McMillan, N. A. (2005) Phosphorylation of HIV Tat by PKR increases interaction with TAR RNA and enhances transcription Virol. J. 2,17-30[CrossRef][Medline]
- Lum, J. J., Pilon, A. A., Sanchez-Dardon, J., Phenix, B. N., Kim, J. E., Mihowich, J., Jamison, K., Hawley-Foss, N., Lynch, D. H., Badley, A. D. (2001) Induction of cell death in HIV-infected macrophages and resting memory CD4 T cells by TRAIL-Apo2L J. Virol. 75,11128-11136[Abstract/Free Full Text]
- Lichtner, M., Marañón, C., Vidalain, P. O., Hanau, D., Lebon, P., Burgart, M., Rouzioux, C., Vullo, V., Yagita, H., Rabourdin-Combe, C., et al (2004) HIV-1 infected dendritic cells induce apoptotic death in infected and uninfected primary CD4+ T lymphocytes AIDS Res. Hum. Retroviruses 20,175-182[CrossRef][Medline]
- Herbeuval, J. P., Boasso, A., Grivel, J. C., Hardy, A. W., Anderson, S. A., Dolan, M. J., Chougnet, C., Lifson, J. D., Shearer, G. M. (2005) TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected patients and its in vitro production by antigen-presenting cells Blood 105,2458-2464
- Vieillard, V., Strominger, J. L., Debre, P. (2005) NK cytotoxicity against CD4+ T cells during HIV-1 infection: a gp41 peptide induces the expression of an NKp44 ligand Proc. Natl. Acad. Sci. USA 102,10981-10986[Abstract/Free Full Text]
- Estaquier, J., Idziorek, T., de Bels, F., Barre-Sinoussi, F., Hurtrel, B., Aubertin, A. M., Venet, A., Mehtali, M., Muchmore, E., Michel, P., et al (1994) Programmed cell death and AIDS: significance of T-cell apoptosis in pathogenic and nonpathogenic primate lentiviral infections Proc. Natl. Acad. Sci. USA 91,9431-9435[Abstract/Free Full Text]
- Miura, Y., Misawa, N., Maeda, N., Inagaki, Y., Tanaka, Y., Ito, M., Kayagaki, N., Yamamoto, N., Yagita, H., Mizusawa, H., et al (2001) Critical contribution of TNF-related apoptosis-inducing ligand (TRAIL) to apoptosis of human CD4+ T cells in HIV-1 infected hu-PBL-NOD-SCID mice J. Exp. Med. 193,651-659[Abstract/Free Full Text]
- Keir, M. E., Stoddart, C. A., Linquist-Stepps, V., Moreno, M. E., McCune, J. M. (2002) IFN-alpha secretion by type 2 predendritic cells up-regulates MHC class I in the HIV-1-infected thymus J. Immunol. 168,325-331[Abstract/Free Full Text]
- Keir, M. E., Rosenberg, M. G., Sandberg, J. K., Jordan, K. A., Wiznia, A., Nixon, D. F., Stoddart, C. A., McCune, J. M. (2002) Generation of CD3+CD8 low thymocytes in the HIV type 1-infected thymus J. Immunol. 169,2788-2796[Abstract/Free Full Text]
- Zagury, D., Lachgar, A., Chams, V., Fall, L. S., Bernard, J., Zagury, J. F., Bizzini, B., Gringeri, A., Santagostino, E., Rappaport, J., et al (1998) Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS Proc. Natl. Acad. Sci. USA 95,3851-3856[Abstract/Free Full Text]
- Coulaud, I. P., Gougeon, M. L., Gomard, E., Descamps, D., Lebon, P., Aboulker, J. P., Bizzini, B., Zagury, D. (1997) A placebo-controlled clinical phase I trial with combined anti-HIV-1 and anti-interferon-alpha immunization AIDS 11,937-938[Medline]
- Lane, H. C., Davey, V., Kovacs, J. A., Feinberg, J., Metcalf, J. A., Herpin, B., Walker, R., Deyton, L., Davey, R. T., Jr, Falloon, J., et al (1990) Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial Ann. Intern. Med. 112,805-811[Medline]
- Riviere, Y., Gresser, I., Guillon, J. C., Tovey, M. G. (1977) Inhibition by anti-interferon serum of lymphocytic choriomeningitis virus disease in suckling mice Proc. Natl. Acad. Sci. USA 74,2135-2139[Abstract/Free Full Text]
- Hahm, B., Trifilo, M.J., Zuniga, E.I., Oldstone, M.B. (2005) Viruses evade the immune system through type I interferon-mediated STAT2-dependent, but STAT1-independent, signaling Immunity 22,247-57[CrossRef][Medline]
- McNally, J.M., Zarozinski, C.C., Lin, M.Y., Brehm, M.A., Chen, H.D., Welsh, R.M. (2001) Attrition of bystander CD8 T cells during virus-induced T-cell and interferon responses J Virol 75,5965-76[Abstract/Free Full Text]
- Bahl, K., Kim, S.K., Calcagno, C., Ghersi, D., Puzone, R., Celada, F., Selin, L.K., Welsh, R.M. (2006) IFN-induced attrition of CD8 T cells in the presence or absence of cognate antigen during the early stages of viral infections J Immunol 176,4284-95[Abstract/Free Full Text]
- Blanco, P., Palucka, A. K., Gill, M., Pascual, V., Banchereau, J. (2001) Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus Science 294,1540-1543[Abstract/Free Full Text]
- Banchereau, J., Paczesny, S., Blanco, P., Bennett, L., Pascual, V., Fay, J., Palucka, A. K. (2003) Dendritic cells: controllers of the immune system and a new promise for immunotherapy Ann. N. Y. Acad. Sci. 987,180-187[Abstract/Free Full Text]
- Perussia, B., Fanning, V., Trinchieri, G. (1985) A leukocyte subset bearing HLA-DR antigens is responsible for in vitro alpha interferon production in response to viruses Nat. Immun. Cell Growth Regul. 4,120-137[Medline]
- Fitzgerald-Bocarsly, P., Feldman, M., Mendelsohn, M., Curl, S., Lopez, C. (1988) Human mononuclear cells which produce interferon-alpha during NK(HSV-FS) assays are HLA-DR positive cells distinct from cytolytic natural killer effectors J. Leukoc. Biol. 43,323-334[Abstract]
- Chehimi, J., Starr, S. E., Kawashima, H., Miller, D. S., Trinchieri, G., Perussia, B., Bandyopadhyay, S. (1989) Dendritic cells and IFN-alpha-producing cells are two functionally distinct non-B, non-monocytic HLA-DR+ cell subsets in human peripheral blood Immunology 68,486-490[Medline]
- Siegal, F., Kadowaki, N., Shodell, M., Fitzgerald-Bocarsly, P., Shah, K., Ho, S., Antonenko, S., Liu, Y. (1999) The nature of the principal type 1 interferon-producing cells in human blood Science 284,1835-1837[Abstract/Free Full Text]
- Grouard, G., Rissoan, M.-C., Filgueira, L., Durand, I., Banchereau, J., Liu, Y.-J. (1997) The enigmatic plasmacytoid T cells develop into dendritic cells with Interleukin 3 and CD40-ligand J. Exp. Med. 185,1101-1111[Abstract/Free Full Text]
- Rissoan, M. C., Soumelis, V., Kadowaki, N., Grouard, G., Briere, F., de Waal Malefyt, R., Liu, Y. J. (1999) Reciprocal control of T helper cell and dendritic cell differentiation Science 283,1183-1186[Abstract/Free Full Text]
- Cella, M., Jarrossay, D., Facchetti, F., Alebardi, O., Nakajima, H., Lanzavecchia, A., Colonna, M. (1999) Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon Nat. Med. 5,919-923[CrossRef][Medline]
- Dzionek, A., Sohma, Y., Nagafune, J., Cella, M., Colonna, M., Facchetti, F., Gunther, G., Johnston, I., Lanzavecchia, A., Nagasaka, T., et al (2001) BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction J. Exp. Med. 194,1823-1834[Abstract/Free Full Text]
- Asselin-Paturel, C., Boonstra, A., Dalod, M., Durand, I., Yessaad, N., Dezutter-Dambuyant, C., Vicari, A., O'Garra, A., Biron, C., Briere, F., et al (2001) Mouse type I IFN-
TOP
PLASMACYTOID DENDRITIC CELLS AND...
HOMING AND CELL INTERACTION
